

November 4, 2022



Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

AUSTIN, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates," or "MTEM"), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that it will present four abstracts and host an in-person Research & Development Day, Friday, November 11, 2022, at The Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting which will be held November 8 – 12, 2022 at the Boston Convention and Exhibition Center in Boston, MA.

The R&D Day event will include in-person presentations by the senior leadership team of Molecular Templates reviewing the technology of next-generation ETBs, the clinical highlights informing development strategies, and the data presented at SITC around its PD-L1 targeting MT-6402 and CTLA-4 targeting MT-8421 programs. The event will be webcasted and take place 11:30am – 12:30pm ET Friday, November 11, 2022, at the Boston Convention Center during SITC's 37th Annual Meeting. A live Q&A session will follow the presentation.

Four abstracts to be presented at SITC include:

Title: A clinical stage engineered toxin body (ETB) targeting PD-L1 (MT-6402) induces peripheral pharmacodynamic responses unique from PD-L1 monoclonal antibodies

Program: MT-6402, PD

Abstract Number: 736

Date: Friday, Nov 11, 2022

Location: Hall C

Title: First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim Data

Program: MT-6402, Clinical

Abstract Number: 764

Date: Friday, Nov 11, 2022

Location: Hall C

Title: Engineered toxin body targeting CTLA-4 (MT-8421) depletes Tregs in the tumor microenvironment and synergizes with α PD-1 to enhance T cell immunity

Program: MT-8421

Abstract Number 817
Date: Thursday, Nov 10, 2022
Location: Hall C

Title: Engineered toxin body targeting TIGIT depletes Tregs in the tumor microenvironment and reduces tumor burden in mice

Program: TIGIT

Abstract Number 1379

Date: Thursday, Nov 10, 2022

Location: Hall C

“We look forward to updating the community on data presented at SITC. We believe the approach MTEM has taken in immuno-oncology is highly differentiated and that we are seeing early signs this approach can provide patient benefit and open up new avenues for targeting PD-L1 and CTLA-4,” said Eric Poma, Chief Executive Officer of Molecular Templates.

To register for the webcast, please click [here](#).

About Molecular Templates

Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “potential,” “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Molecular Templates may identify forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the safety or potential efficacy of Molecular Templates’ drug or biologic candidates, including the anticipated benefits of MT-6402, MT-5111, MT-0169, and MT-8421 and Molecular Templates’ next-generation ETBs; statements relating to the development of MT-6402, MT-5111, MT-0169, MT-8421 and next-generation ETBs; the expected timing for submitting various IND applications and conducting studies, opening sites and generating data; the expected participation and presentation at upcoming conferences; the expected timing for providing updates on MT-6402, MT-5111, MT-0169, and MT-8421, as well as Molecular Templates’ earlier stage pipeline of ETBs, including any pre-clinical data; and Molecular Templates’ belief that its proprietary biologic drug platform technology, or ETBs, provides for a differentiated mechanism of action for cancer and other serious diseases.

Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process; whether Molecular Templates' cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; Molecular Templates' ability to timely enroll patients in its clinical trials; the ability of Molecular Templates' to protect its intellectual property rights; risks from global pandemics including COVID-19; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Molecular Templates' filings with the SEC. There can be no assurance that any of Molecular Templates' drug or biologic candidates will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Contact:

Dr. Grace Kim
Head of Investor Relations
grace.kim@mtem.com



Source: Molecular Templates, Inc.